Drug-induced hepatotoxicity: A review

Journal of Applied Pharmaceutical Science

Volumn 2, Issue 5, 2012, Pages 233-243

  Pandit, Aashish ^a   Sachdeva, Tarun ^a   Bafna, Pallavi ^a  

^a Rayat Institute of Pharmacy   (India)

Author keywords

Drug; Hepatotoxicity; Liver; Mechanism

Indexed keywords

EID: 84875193614     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: 10.7324/JAPS.2012.2541     Document Type: Review

References (114)

1. Abajo F.J., Montero D., Madurga M., Garcia Rodriguez L.A. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004; 58: 71-80.
2. Aceti A., Pasquazzi C., Zechini B., De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV. The role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr. 2002; 29: 41-48.
3. Aithal G.P. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Expert Opin Drug Saf. 2004; 3: 519-523.
4. Aithal G.P. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol. 2011; 7: 139-150.
5. Alonso J.J., Osorio J.M., Cabello F.G., Osa A.L., Leon L., Garcia J.D.M. Atorvastatin induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Arch Intern Med. 1999; 159: 1811-1812.
6. Ansari A., Elliott T., Baburajan B., Mayhead P., Donohue J.O., Anderson J.S., Dudley J. Long-term outcome of using allopurinol cotherapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther. 2008; 28: 734-741.
7. Basseri S., Austin R.C. ER stress and lipogenesis: a slippery slope toward hepatic steatosis. Dev Cell. 2008; 15: 795-796.
8. Benichou C. Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J Hepatol. 1990; 11: 272-276.
9. Bertolami M.C. Mechanisms of hepatotoxicity. Arq Bras de Cardiol. 2005; 85(5): 25-27.
10. Bissell D., Gores G., Laskin D., Hoofnagle J.H. Drug-induced liver injury: mechanisms and test systems. Hepatol. 2001; 33: 1009-1013.
11. Bissuel F., Bruneel F., Habersetzer F., Chassar D., Cotte L., Chevallier M., Bernuau M., Lucet J.C., Trepo C. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med. 1994; 235: 367-371.
12. Bjornsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand. 2008; 118: 281-290.
13. Bolder U., Trang N.V., Hagey L.R., Schteingart C.D., Ton-Nu H.T., Cerre C. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterol. 1999; 117: 962-971.
14. Bonfanti P., Landonio S., Ricci E., Artinelli C., Fortuna P., Faggion I., Quirino T. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001; 27: 316-318.
15. Bonkovsky H., Blanchette P., Schned A. Severe liver injury due to phenelzine with unique hepatic deposition of extracellular material. Am J Med. 1986; 80: 689-692.
16. Bort R., Ponsoda X., Jover R., Gomez-Lechon M.J., Castell J.V. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther. 1999; 288: 65-72.
17. Breen D.P., Marinaki A.M., Arenas M., Hayes P.C. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl. 2005: 11: 826-833.
18. Bricquir Y., Larrey D., Blanc P., Pageaux G.P., Michel H. Tianeptine-an instance of drug-induced hepatotoxicity predicted by prospective experimental studies. J Hepatol. 1994; 21: 771-773.
19. Brinkman K., Hofstede K., Burger D., Smeitink J., Koopmans P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998; 12: 1735-1744.
20. Brody G.L., Sweet R.B. Halothane anesthesia as a possible cause of massive hepatic necrosis. Anesthesiol. 1963; 24: 29-37.
21. Conzen P. Effect of inhalational anesthetics on the liver. Baillierere's Best Practice &Research Clinical Anesthesiology. 1993; 4: 1015-1034.
22. Caldwell S.H., Hespenheide E.E., Borstel R.W. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Digest Dis Sci. 2001; 46: 376.
23. Carbonero L., Nunez M., Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003; 4: 115-120.
24. Chandran V., Schentag C.T., Gladman D.D. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol. 2008; 35: 469-471.
25. Chen H., Huang C.Y., Wilson M.W., Lay L.T., Robertson L.W., Chow C.K., Glauert H.P. Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cell proliferation and toxicity in Sprague-Dawley rats. Carcinogenesis. 1994; 15: 2847-2850.
26. Chitturi S., George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid lowering agents, psychotropic drugs. Semin Liver Dis. 2002; 22: 169-183.
27. Cohen D.E., Anania F.A., Chalasani N. National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol. 2006; 97: 77-81.
28. Connor N.O., Dargan P.I., Jones A.L. Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM: An International Journal of Medicine. 2003; 96: 787-791.
29. Cooper C., Parbhakar M., Angel J. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals co infected with hepatitis C virus and HIV. Clin Infect Dis. 2002; 34: 1259-1263.
30. Curran R.D., Billiar T.R., Stuehr D.J., Ochoa J.B., Harbrechet B.G., Flint S.G. Multiple cytokines are required to induce hepatocyte nitric oxide production and inhibit total protein synthesis. Ann Surg. 1990; 212: 462-471.
31. Dalton T.A., Berry R.S. Hepatotoxicity associated with sustained-release niacin. Am J Med. 1992; 93(1): 102-104.
32. Desouza C., Keebler M., Namara D.B., Fonseca V. Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs. 2002; 62: 605-616.
33. Desta Z., Soukhova N.V., Flockhart D.A. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother. 2001; 45: 382-392.
34. Dix K.J., Coleman D.P., Jeffcoat A.R. Comparative metabolism and disposition of gemfibrozil in male and female Sprague-Dawley rats and Syrian golden hamsters. Drug Metab Dispos. 1999; 27: 138-146.
35. Dufour J.F.J., Turner T.J., Arias I.M. Nitric oxide blocks bile canalicular contraction by inhibiting inositol triphosphate-dependent calcium mobilization. Gastroenterol. 1995; 108: 841-849.
36. Dybing E. Activation of methyl dopa, paracetamol and frusemide by human liver microsomes. Acta Pharmacol Toxicol. 1977; 41: 89-93.
37. Elisson E., Kenna J.G. Cytochrome P4502E1 is a cell surface auto antigen in halothane hepatitis. Mol Pharmacol. 1996; 50: 573-582.
38. Etchason J.A., Miller T.D., Squires R.W., Allison T.G., Gau G.T., Marttila J.K. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin Proceed. 1991; 66: 23-28.
39. Fallahian F. Halothane Induced Hepatitis. Shiraz e-medical Journal. 2009; 10: 209-220.
40. Forbes G.M., Jeffrey G.P., Shilkin K.B., Reed W.D. Carbamazepine hepatotoxicity: Another case of the vanishing bile duct syndrome. Gastroenterol. 1992; 102: 1385-1388.
41. Fromenty B., Freneaux E., Labbe G., Deschamps D., Larrey D., Letteron P., Pessayre D. Tianeptine, a new tricyclic antidepressant metabolized by ß-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice. Biochem Pharmacol. 1989; 38: 3743-3751.
42. Girling D.J. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle. 1978; 59: 13-32.
43. Gisolf E., Dreezen C., Danner, Weel J.L., Weverling G.J. Risk factors for hepatotoxicity in HIV-1 infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis. 2000; 3: 1234-1239.
44. Grimbert S., Pessayre D., Degott C., Benhamou J.P. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Digest Dis Sci. 1994; 39: 2032-2033.
45. Helliwell P.S., Taylor W.J. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs-comparison of drugs and adverse reactions. J Rheumatol. 2008; 35: 472-476.
46. Hodis H.N. Acute hepatic failure associated with the use of lowdose sustained-release niacin. JAMA. 1990; 264: 181.
47. Horsmans Y., Desager J.P., Harvengt C. Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor). Pharmacol Toxicol. 1990; 67: 336-339.
48. Horst D., Grace N., Le Compte P. Prolonged cholestasis and progressive hepatic fibrosis following imipramine therapy. Gastroenterology. 1980; 79: 550-554.
49. Horton R.A., Ceppi E.D., Knowles R.G., Titheradges M.A. Inhibition of hepatic gluconeogenesis by nitric oxide: a comparison with endotoxic shock. Biochem J. 1994; 299: 735-739.
50. Huang Y.S., Chern H.D., Su W.J., Wu J.C., Lai S.L., Yang S.Y., Chang F.Y., Lee S.D. Cytochrome P450 2E1genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.
51. Hummer M., Kury M., Kurzthaler I., Oberbauer H., Miller C., Fleischhacker W. Hepatotoxicity of clozapine. J Clin Psychopharm. 1997; 17: 314-317.
52. Ishak K., Irey N. Hepatic injury associated with the phenothiazines. Arch Path. 1972; 93: 283-304.
53. Jacobson T.A. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol. 2006; 97: 44-51
54. Jeffrey LA and Allan T. Handbook of Psychiatric Drugs. John Wiley and Sons Ltd., Chichester UK (2006) 34.
55. Jenner A.M., Timbrell J.A. In vitro microsomal metabolism of hydrazine. Xenobiotica 1995; 25: 599-609.
56. Jenner A.M., Timbrell J.A. Influence of inducers and inhibitors of cytochrome P450 on the hepatotoxicity of hydrazine in vivo. Arch Toxicol. 1994; 68: 349-357.
57. Jobanputra P., Amarasena R., Maggs F., Jubb R., Homer D. Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord. 2008; 9: 48.
58. Johnson S., Chan J., Bennett C. Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen. Ann Intern Med. 2002; 137: 146-147.
59. Kanathur N., Mathai M.G., Byrd R.P., Fields C.L., Roy T.M. Simvastatin-Diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tennessee Med. 2001; 94: 339-341.
60. Kharasch E.D., Hankins D., Mautz D., Thummel K.E. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. The Lancet. 1996; 347: 1367-1371.
61. Kloss M.W., Rosen G.M., Rauckman E.J. Cocaine-medicated hepatotoxicity. A critical review. Biochem Pharmacol. 1984; 33: 169-173.
62. Kontorinis N., Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003; 5: 36-43.
63. Kremer J.M. Toward a better understanding of methotrexate. Arthritis Rheum. 2004; 50: 1370-1382.
64. Landmesser U., Bahlmann F., Mueller M., Spiekermann S., Kirchhoff N., Schulz S. Simvastatin versus ezetimibe: pleiotropic and lipid lowering effects on endothelial function in humans. Circulation. 2005; 111: 2356-2363.
65. Leist M., Gantner F., Kunstle G., Wendel A. Cytokine-mediated hepatic apoptosis. Rev Physiol Biochem Pharmacol. 1998; 133: 109-155.
66. Leonard S.W., Goffard R.W., Humphrey D.C. Treatment of hypertension with methyl dopa alone or combined with Guanethedine: A report of 63 cases. Am Heart J. 1965; 69: 610-618.
67. Lewis, J.H. (2007). Nonsteroidal anti-inflammatory drugs and leukotriene receptor antagonists: pathology and clinical presentation of hepatotoxicity. In N. Kaplowitz, L.D. DeLeve (Eds.) Drug-induced liver disease. (pp. 377-390). New York: Informa Healthcare USA.
68. Lui S.Y., Steve T., Lam M., Cheung Eric F.C. Case Report: Possible olanzapine-induced hepatotoxicity in a young Chinese patient. Hong Kong Med J. 2009; 15: 5.
69. Maffei F.R., Carini M. The inhibitory effect of pyrazinamide on microsomal monooxygenase activities is related to the binding to reduced cytochrome P-450. Pharmacol Res Commun. 1980; 12: 523-537.
70. Martinez E., Blanco J., Arnaiz J.A., Perez-Cuevas J.B., Mocroft A., Cruceta A., Marcos M.A., Milinkovic A., Garcia-Viejo M.A., Mallolas J., Carne X., Phillips A., Gatell J.M. Hepatotoxicity in HIV-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268.
71. Masubuchi Y., Yamada S., Horie T. Possible mechanisms of hepatocyte injury induced by diphenylamine and its structurally related NSAIDS. J Pharmacol Exp Ther. 2000; 292: 982-987.
72. Mitchell J.R., Jollow D.J., Potter W.Z., Davis D.C., Gillette J.R., Brodie B.B. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther. 1973; 187: 185-194.
73. Mitchell M.C., Boitnott J.K., Arregui A., Maddrey W.C. Granulomatous hepatitis associated with carbamazepine therapy. Am J Med. 1981; 71: 733-735.
74. Mohi-ud-din R., Lewis J.H. Drug and chemical-induced cholestasis. Clin Liver Dis. 2004; 8: 95-132.
75. Nakad A., Bataille L., Hamoir V., Sempoux C., Horsman Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet. 1999; 353: 1763-1764.
76. Nishimura Y., Kurata N., Sakurai E., Yasuhara H. Inhibitory effect of anti-tuberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci. 2004; 96: 293-300.
77. Njoku D., Laster M.J., Gong D.H. Biotransformation of halothane, enflurane, isoflurane and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anest Analg. 1997; 84: 173-178.
78. Nunez M., Lana R., Mendoza J., Martin-Carbonero L., Eger E.I., Reed G.F., Martin J.L. Risk factors for severe hepatic injury following the introduction of HAART. J Acquir Immune Def Syndr. 2001; 27: 426-431.
79. Nunez M. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. J Hepat. 2006; 44: 132-139.
80. Ostapowicz G., Fontana R.J., Schiodt F.V., Larson A., Davron J.T., Steven H.B., Timothy M., Reish J. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002; 137: 947-954.
81. Padma V.V., Suja V., Shyamala D.C.S., Prema. Hepatoprotective effect of Liv-52 on antitubercular drug-induced hepatotoxicity in rats. Fitoterapia. 1998; 69(6): 520-522.
82. Pai V., Koranyi K., Nahata M. Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection. Pharmacother. 2000; 20: 1135-1140.
83. Palmon R., Koo B., Shoultz D., Dieterich D. Lack of hepatotoxicity associated with non nucleoside reverse transcriptase inhibitors. J Acquir Immun Defic Syndr. 2002; 29: 340-345.
84. Pelli N., Setti M., Ceppa P., Toncini C., Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroen Hepat. 2003; 15: 921-924.
85. Popovic M., Nierkens S., Pieters R., Uetrecht J. Investigating the role of 2-phenylpropenal in felbamate-induced idiosyncratic drug reactions. Chem Res Toxicol. 2004; 17: 1568-1576.
86. Reichle F.M., Conzen P.F. Halogenated inhalational anesthetics. Best Practice &Research Clin Anaesthesiol. 2003; 17: 29-46.
87. Reimund E., Ramos A. Niacin-induced hepatitis and thrombocytopenia after 10 years of niacin use. J Clin Gastroenterol. 1994; 18: 270-271.
88. Ricaurte B., Guirguis A., Taylor H.C., Zabriskie D. Simvastatinamiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Annals of Pharmacotherapy. 2006; 40(4): 753-757.
89. Rodman J.S., Deutsch D.J., Gutman S.I. Methyl dopa hepatitis. A report of six cases and a review of the literature. Am J Med. 1976; 60: 941-948.
90. Ross J.A., Monk S.J., Duffy S.W. Effect of Nitrous Oxide on halothane induced hepatotoxicity in hypoxic enzyme induced rats. Br J Anaest. 1984; 56: 527-533.
91. Satoh H., Fukuda Y., Anderson D.K. Immunological studies on the mechanism of halothane induced hepatotoxicity: immunohistochemical evidence of trifluoro-acetylated hepatocytes. J Pharmacol Exp Ther. 1985; 223: 857-862.
92. Selim K., Kaplowitz N. Hepatotoxicity of Psychotropic Drugs. Hepatology. 2003; 29: 1348-1350.
93. Sgro C., Clinard F., Ouazir K., Chanay H., Allard C., Guilleminet C., Lenoir C., Lemoine A., Hillon P. Incidence of druginduced hepatic injuries: A french population-based study. Hepatology. 2002; 36: 451-455.
94. Sharma A., Chakraborti K.K., Handa S.S. Anti-hepatotoxic activity of some Indian herbal formulations as compared to silymarin. Fitoterapia. 1991; 62: 229-235.
95. Sipes I.G., Brown B.R. An animal model of hepatotoxicity associated with halothane anesthesia. Anesthesiology. 1976; 45: 622-628.
96. Smythe M.A., Umstead J.S. Phenytoin hepatotoxicity: a review of the literature. Ann Pharmacotherapy. 1989; 23: 13-18.
97. Sokolove J., Greenberg D.J., Strand V., Curtis J.R., Kavanaugh A., Kremer J., Anofrei A., Reed G., Calabrese L., Hooper M. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010; 69: 1612-1617.
98. Sparrow M.P., Hande S.A., Friedman S., Cao D., Hanauer S.B. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007; 5: 209-214.
99. Stachlewitz R., Arteel G., Raleigh J., Connor H., Mason R., Thurman R. Development and characterization of a new model of tacrineinduced hepatotoxicity: role of the sympathetic nervous system and hypoxia-reoxygenation. J Pharmacol Exp Ther. 1997; 282: 1591-1599.
100. Steven Leeder J., Pirmohamad M. Drug induced liver Diseases. United States of America: Informa Healthcare Publishers. Chapter 18, Anticonvulsant Agents; p. 425-436.
101. Strand V., Kimberly R., Isaacs J.D. Biologic therapies in rheumatology: lessons learned future directions Nat Rev Drug Discov.2007; 6: 75-92.
102. Subramonium A., Pushpangadan P. Development of Phytomedicines for liver diseases. Indian J Pharmacology. 1999; 31: 166-175.
103. Sulkowski M., Thomas D., Chaisson R., Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. J Am Med Assoc. 2000; 283: 74-80.
104. Sulkowski M., Thomas D., Mehta S., Chaisson, Moore R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002; 35: 182-189.
105. Sulkowski M. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis. 2003; 23: 183-194.
106. Tarazi E.M., Harter J.G., Zimmerman H.J., Ishak K.G., Eaton RA. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology. 1993; 104: 569-574.
107. Tostmann A., Boeree M.J., Aarnoutse R.E., Lange W.C.M., Vander Ven A.J., Dekhuijzen R. Anti-tuberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol. 2008; 23: 192-202.
108. Walker A.M. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1997; 40: 201-208.
109. Walker U., Setzer B., Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reversetranscriptase inhibitors. AIDS. 2002; 16: 2165-2173.
110. Watkins P.B., Schade R., Mills A.S., Carithers R.L., Thiel D.H. Fatal hepatic necrosis associated with parenteral gold therapy. Dig Dis Sci. 1988; 33: 1025-1029.
111. Wen X., Wang J.S., Neuvonen P.J., Backman J.T. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol. 2002; 57: 799-804.
112. Wit F., Weverling G., Weel J., Jurrians S., Lange J. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis .2002; 186: 23-31.
113. Zimmerman H.J. Update on hepatotoxicity due to classes of drugs in common clinical use: non-steroidal drugs, anti-inflammatory drugs, antibiotics, anti-hypertensives and cardiac and psychotropic agents. Semin Liver Dis. 1990; 10: 322-338.
114. Zimmerman H.J. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. 2nd ed. Lippincott Williams and Wilkins, Philadelphia (1999) 483-498.